Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01304784 · ClinicalTrials.gov registry record · Phase 1
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
A Phase 1 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT01304784 is a Phase 1 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 100 participants.
The verdict
NCT01304784, a Phase 1 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Interventions
- DRUG Cisplatin, Capecitabine, Trastuzumab and MM-111
- DRUG Lapatinib +/- Trastuzumab and MM-111
- DRUG Paclitaxel, Trastuzumab and MM-111
- DRUG Lapatinib, trastuzumab, paclitaxel, and MM-111
- DRUG Docetaxel, trastuzumab and MM-111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01304784
The ClinicalTrials.gov registry entry for NCT01304784 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin, Capecitabine, Trastuzumab and MM-111 is the first listed.
NCT01304784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01304784 about?
NCT01304784 is a clinical study titled "A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer". This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
What is the current status of trial NCT01304784?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2011-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01304784?
The interventions under investigation include: Cisplatin, Capecitabine, Trastuzumab and MM-111 (DRUG), Lapatinib +/- Trastuzumab and MM-111 (DRUG), Paclitaxel, Trastuzumab and MM-111 (DRUG), Lapatinib, trastuzumab, paclitaxel, and MM-111 (DRUG), Docetaxel, trastuzumab and MM-111 (DRUG).
Who is sponsoring clinical trial NCT01304784?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.